Benitec Biopharma’s pipeline of in-house and partnered programs to develop therapeutics for chronic and life-threatening conditions is based on our proprietary technology, DNA-directed RNA(ddRNAi). View our out-licensed programs
Due to its demonstrated ability to effect long-lasting gene silencing, once proven in human trials, ddRNAi technology has significant potential to treat or cure a broad range of human diseases and conditions. These include cancers, neurological diseases, infectious diseases, autoimmune diseases, genetic diseases and other afflictions that are associated with the expression of a small number of key genes.
Our in-house pipeline is summarized below, In-house pipeline
. View our out-licensed programs Out-licensed programs Successful development of therapeutic products in just one of these programs would be a major breakthrough in medical therapy.
Tacere Therapeutics develops human therapeutics based on RNA interference (RNAi) and ddRNAi gene-silencing technology from Benitec Biopharma. Using this approach, the drugs we create promise long term treatment or cure with a single dose.
Tacere Therapeutics is a Benitec Biopharma company.
|BNTC News: Current Report Filing (8-k)||09/16/2022 09:00:28 AM|
|BNTC News: Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering||09/16/2022 08:42:36 AM|
|BNTC News: Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering||09/12/2022 10:06:00 PM|
|BNTC News: Securities Registration Statement (s-1/a)||09/12/2022 04:21:45 PM|
|BNTC News: Securities Registration Statement (s-1/a)||09/09/2022 06:02:42 AM|